NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00219739,STI571 ProspectIve RandomIzed Trial: SPIRIT,https://clinicaltrials.gov/study/NCT00219739,SPIRIT,COMPLETED,"To test whether increasing the dose of imatinib or combining it with IFNalpha or ara-C increases the rate of molecular response (as measured by the decrease in BCR-ABL transcripts after 12 months of treatment) in patients with previously untreated CML in chronic phase.

To compare overall survival in a selected arm according to molecular response at 1 year from randomization with the reference arm.",NO,Chronic Myeloid Leukemia,DRUG: Imatinib mesylate 400 mg|DRUG: Imatinib mesylate 600 mg|DRUG: Imatinib 400 mg + Peg-Interferon|DRUG: Imatinib mesylate 400 mg + Cytarabine,Overall survival improvement,"Molecular response improvement at 1 year, 1 year|Hematological, cytogenetic responses improvement, 1 year|Duration of responses improvement|Survival without progression improvement|Acceptable toxicity",,Poitiers University Hospital,"Ministry of Health, France|Novartis|Roche Pharma AG",ALL,"ADULT, OLDER_ADULT",PHASE3,789,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,SPIRIT,2003-09,2014-12,2014-12,2005-09-22,,2020-04-13,"University Hospital, Poitiers, 86021, France",
